{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:07:36Z","timestamp":1790755656698,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T00:00:00Z","timestamp":1530576000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s10067-018-4174-3","type":"journal-article","created":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T02:05:24Z","timestamp":1530583524000},"page":"2113-2123","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Oral cyclophosphamide in treatment of patients with refractory idiopathic inflammatory myopathies: a retrospective observational study"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7216-7219","authenticated-orcid":false,"given":"Sangmee","family":"Bae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Charles-Schoeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,3]]},"reference":[{"key":"4174_CR1","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403\u2013407","journal-title":"N Engl J Med"},{"key":"4174_CR2","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344\u2013347","journal-title":"N Engl J Med"},{"key":"4174_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/joim.12511","volume":"280","author":"CV Oddis","year":"2016","unstructured":"Oddis CV (2016) Update on the pharmacological treatment of adult myositis. J Intern Med 280:63\u201374","journal-title":"J Intern Med"},{"key":"4174_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJM197908023010503","volume":"301","author":"AS Fauci","year":"1979","unstructured":"Fauci AS, Katz P, Haynes BF, Wolff SM (1979) Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 301:235\u2013238","journal-title":"N Engl J Med"},{"key":"4174_CR5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.7326\/0003-4819-125-7-199610010-00003","volume":"125","author":"MF Gourley","year":"1996","unstructured":"Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J et al (1996) Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 125:549\u2013557","journal-title":"Ann Intern Med"},{"key":"4174_CR6","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655\u20132666","journal-title":"N Engl J Med"},{"key":"4174_CR7","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/rheumatology\/kel112","volume":"46","author":"Y Yamasaki","year":"2007","unstructured":"Yamasaki Y, Yamada H, Yamasaki M, Ohkubo M, Azuma K, Matsuoka S et al (2007) Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis\/dermatomyositis. Rheumatology (Oxford) 46:124\u2013130","journal-title":"Rheumatology (Oxford)"},{"key":"4174_CR8","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.2169\/internalmedicine.47.1289","volume":"47","author":"S Tsujimura","year":"2008","unstructured":"Tsujimura S, Saito K, Tanaka Y (2008) Complete resolution of dermatomyositis with refractory cutaneous vasculitis by intravenous cyclophosphamide pulse therapy. Intern Med 47:1935\u20131940","journal-title":"Intern Med"},{"key":"4174_CR9","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/08916930600623767","volume":"39","author":"P Mielnik","year":"2006","unstructured":"Mielnik P, Wiesik-Szewczyk E, Olesinska M, Chwalinska-Sadowska H, Zabek J (2006) Clinical features and prognosis of patients with idiopathic inflammatory myopathies and anti-jo-1 antibodies. Autoimmunity 39:243\u2013247","journal-title":"Autoimmunity"},{"key":"4174_CR10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0733-8635(02)00021-9","volume":"20","author":"RD Sontheimer","year":"2002","unstructured":"Sontheimer RD (2002) Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin 20:387\u2013408","journal-title":"Dermatol Clin"},{"key":"4174_CR11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","volume":"14","author":"JE Hoogendijk","year":"2004","unstructured":"Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR et al (2004) 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, the Netherlands. Neuromuscul Disord 14:337\u2013345","journal-title":"Neuromuscul Disord"},{"key":"4174_CR12","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/ana.410380504","volume":"38","author":"RC Griggs","year":"1995","unstructured":"Griggs RC, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR et al (1995) Inclusion body myositis and myopathies. Ann Neurol 38:705\u2013713","journal-title":"Ann Neurol"},{"key":"4174_CR13","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/acr.20035","volume":"62","author":"LG Rider","year":"2010","unstructured":"Rider LG, Koziol D, Giannini EH, Jain MS, Smith MR, Whitney-Mahoney K et al (2010) Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res 62:465\u2013472","journal-title":"Arthritis Care Res"},{"key":"4174_CR14","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1002\/art.1780401109","volume":"40","author":"LG Rider","year":"1997","unstructured":"Rider LG, Feldman BM, Perez MD, Rennebohm RM, Lindsley CB, Zemel LS et al (1997) Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile dermatomyositis disease activity collaborative study group. Arthritis Rheum 40:1976\u20131983","journal-title":"Arthritis Rheum"},{"key":"4174_CR15","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al (1982) Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 5:649\u2013655","journal-title":"Am J Clin Oncol"},{"key":"4174_CR16","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/bjc.1993.140","volume":"67","author":"JB Sorensen","year":"1993","unstructured":"Sorensen JB, Klee M, Palshof T, Hansen HH (1993) Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer 67:773\u2013775","journal-title":"Br J Cancer"},{"key":"4174_CR17","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"CV Oddis","year":"2013","unstructured":"Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65:314\u2013324","journal-title":"Arthritis Rheum"},{"key":"4174_CR18","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/art.23571","volume":"59","author":"M Fathi","year":"2008","unstructured":"Fathi M, Vikgren J, Boijsen M, Tylen U, Jorfeldt L, Tornling G et al (2008) Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 59:677\u2013685","journal-title":"Arthritis Rheum"},{"key":"4174_CR19","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1183\/09031936.00017711","volume":"37","author":"G Raghu","year":"2011","unstructured":"Raghu G (2011) Idiopathic pulmonary fibrosis: guidelines for diagnosis and clinical management have advanced from consensus-based in 2000 to evidence-based in 2011. Eur Respir J 37:743\u2013746","journal-title":"Eur Respir J"},{"key":"4174_CR20","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.3899\/jrheum.161217","volume":"44","author":"N Sharma","year":"2017","unstructured":"Sharma N, Putman MS, Vij R, Strek ME, Dua A (2017) Myositis-associated interstitial lung disease: predictors of failure of conventional treatment and response to tacrolimus in a us cohort. J Rheumatol 44:1612\u20131618","journal-title":"J Rheumatol"},{"key":"4174_CR21","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK et al (2011) An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788\u2013824","journal-title":"Am J Respir Crit Care Med"},{"key":"4174_CR22","doi-asserted-by":"publisher","first-page":"76","DOI":"10.7326\/0003-4819-98-1-76","volume":"98","author":"AS Fauci","year":"1983","unstructured":"Fauci AS, Haynes BF, Katz P, Wolff SM (1983) Wegener\u2019s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 98:76\u201385","journal-title":"Ann Intern Med"},{"key":"4174_CR23","doi-asserted-by":"publisher","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","volume":"116","author":"GS Hoffman","year":"1992","unstructured":"Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD et al (1992) Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116:488\u2013498","journal-title":"Ann Intern Med"},{"key":"4174_CR24","doi-asserted-by":"publisher","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","volume":"150","author":"K Groot de","year":"2009","unstructured":"de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL et al (2009) Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 150:670\u2013680","journal-title":"Ann Intern Med"},{"key":"4174_CR25","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","volume":"71","author":"L Harper","year":"2012","unstructured":"Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O et al (2012) Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 71:955\u2013960","journal-title":"Ann Rheum Dis"},{"key":"4174_CR26","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/1529-0131(199807)41:7<1215::AID-ART11>3.0.CO;2-Y","volume":"41","author":"A Schnabel","year":"1998","unstructured":"Schnabel A, Reuter M, Gross WL (1998) Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum 41:1215\u20131220","journal-title":"Arthritis Rheum"},{"key":"4174_CR27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2169\/internalmedicine.36.519","volume":"36","author":"T Shinohara","year":"1997","unstructured":"Shinohara T, Hidaka T, Matsuki Y, Ishizuka T, Takamizawa M, Kawakami M et al (1997) Rapidly progressive interstitial lung disease associated with dermatomyositis responding to intravenous cyclophosphamide pulse therapy. Intern Med 36:519\u2013523","journal-title":"Intern Med"},{"key":"4174_CR28","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10067-014-2803-z","volume":"34","author":"Y Ge","year":"2015","unstructured":"Ge Y, Peng Q, Zhang S, Zhou H, Lu X, Wang G (2015) Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review. Clin Rheumatol 34:99\u2013105","journal-title":"Clin Rheumatol"},{"key":"4174_CR29","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/art.40418","volume":"70","author":"CT Deakin","year":"2018","unstructured":"Deakin CT, Campanilho-Marques R, Simou S, Moraitis E, Wedderburn LR, Pullenayegum E et al (2018) Efficacy and safety of cyclophosphamide treatment in severe juvenile dermatomyositis shown by marginal structural modelling. Arthritis Rheum 70:785\u2013793","journal-title":"Arthritis Rheum"},{"key":"4174_CR30","doi-asserted-by":"crossref","unstructured":"Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010;62:2757\u20132766","DOI":"10.1002\/art.27572"},{"key":"4174_CR31","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1212\/NXI.0000000000000096","volume":"2","author":"S Ramanathan","year":"2015","unstructured":"Ramanathan S, Langguth D, Hardy TA, Garg N, Bundell C, Rojana-Udomsart A et al (2015) Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy. Neurol Neuroimmunol Neuroinflamm 2:e96","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"4174_CR32","first-page":"102","volume":"14","author":"H Takizawa","year":"1987","unstructured":"Takizawa H, Shiga J, Moroi Y, Miyachi S, Nishiwaki M, Miyamoto T (1987) Interstitial lung disease in dermatomyositis: clinicopathological study. J Rheumatol 14:102\u2013107","journal-title":"J Rheumatol"},{"key":"4174_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/01.md.0000109755.65914.5e","volume":"83","author":"K Danko","year":"2004","unstructured":"Danko K, Ponyi A, Constantin T, Borgulya G, Szegedi G (2004) Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore) 83:35\u201342","journal-title":"Medicine (Baltimore)"},{"key":"4174_CR34","first-page":"58","volume":"32","author":"T Fujisawa","year":"2005","unstructured":"Fujisawa T, Suda T, Nakamura Y, Enomoto N, Ide K, Toyoshima M et al (2005) Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol 32:58\u201364","journal-title":"J Rheumatol"},{"key":"4174_CR35","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s10067-009-1110-6","volume":"28","author":"IJ Chen","year":"2009","unstructured":"Chen IJ, Jan Wu YJ, Lin CW, Fan KW, Luo SF, Ho HH et al (2009) Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol 28:639\u2013646","journal-title":"Clin Rheumatol"},{"key":"4174_CR36","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1002\/art.30513","volume":"63","author":"I Marie","year":"2011","unstructured":"Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF (2011) Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 63:3439\u20133447","journal-title":"Arthritis Rheum"},{"key":"4174_CR37","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S0140-6736(76)90151-3","volume":"1","author":"F Appelbaum","year":"1976","unstructured":"Appelbaum F, Strauchen JA, Graw RG Jr, Savage DD, Kent KM, Ferrans VJ et al (1976) Acute lethal carditis caused by high-dose combination chemotherapy. A unique clinical and pathological entity. Lancet 1:58\u201362","journal-title":"Lancet"},{"key":"4174_CR38","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJM198603063141004","volume":"314","author":"HA Austin 3rd","year":"1986","unstructured":"Austin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH et al (1986) Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314:614\u2013619","journal-title":"N Engl J Med"},{"key":"4174_CR39","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.2215\/CJN.02670409","volume":"4","author":"A McKinley","year":"2009","unstructured":"McKinley A, Park E, Spetie D, Hackshaw KV, Nagaraja S, Hebert LA et al (2009) Oral cyclophosphamide for lupus glomerulonephritis: an underused therapeutic option. Clin J Am Soc Nephrol 4:1754\u20131760","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-4174-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4174-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4174-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T19:20:15Z","timestamp":1562095215000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-4174-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,3]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["4174"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-4174-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,3]]},"assertion":[{"value":"28 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}